Publications

At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward. 

Date
Subject: ISB 1442
All BEAT® Antibody Engineering Platform Cell Line Development ISB 1342 ISB 1442 ISB 2001 ISB 830
Title Lead Author Journal
12/12/2022 ISB 1442 Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (PDF) Jiang T. et al. American Society of Hematology Annual Meeting
12/12/2022 ISB 1442 Presentation: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (PDF) Jiang T. et al. Presentation at the American Society of Hematology Annual Meeting
12/11/2022 ISB 1442 Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (PDF) Sammicheli S. et al. American Society of Hematology Annual Meeting
12/11/2022 ISB 1442 Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (PDF) Sammicheli S. et al. Presentation at the American Society of Hematology Annual Meeting
06/10/2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies (PDF) Sammicheli S. et al. Presentation during EHA2022
04/13/2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies (PDF) Sammicheli S. et al. American Association for Cancer Research Annual Meeting
12/10/2021 ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma (PDF) Sammicheli S. et al. Presentation at the American Society of Hematology Annual Meeting
11/04/2021 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma Sammicheli S. et al. American Society of Hematology Annual Meeting

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.